CELLIPONT BIOSERVICES
Live / Registered — Registered (as of 30 Apr 2024)
What this means for you
Registered since 30 Apr 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97251361
- Registration number
- 7375156
- Mark type
- Stylized text
- Filed
- 03 Feb 2022
- Published for opposition
- 04 Jul 2023
- Registered
- 30 Apr 2024
- Attorney of record
- Paul J. Kennedy
Goods and services
- Class 040 — Treatment of materials: Manufacturing services for others in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals, namely, custom manufacture of pharmaceuticals, chemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing services for others in the fields of mammalian cell banks, plasmids, purified mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians, namely, custom manufacture of pharmaceuticals, chemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing process consulting; Production in the nature of custom manufacture of cell lines for others using lentivirus technology; Production in the nature of custom manufacture of a recombinant or manipulated lentivirus; Production in the nature of custom manufacture of mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians
- Class 042 — Scientific and technological services: Research and development in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; scientific research and technical research services, namely, research and development in the fields of assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting services, namely, research and development in the fields of assaying, and purifying mitochondria, cell lysates, adenovirus, adeno-associated virus (AAV), bacteriophage, lentivirus, retroviruses and other viruses found in mammalians; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for others, namely, cGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the fields of gene therapy, modified gene therapy, modified cell therapy, cell therapy, tissue engineering and biopharmaceuticals; CDMO (Contract Development and Manufacturing Organization) services, namely, pharmaceutical drug development services; material testing; product quality testing; scientific laboratory services; scientific research
- Class 045 — Legal and security services: Providing regulatory compliance and regulatory compliance consultation and advisory services with respect to relevant state and federal law for organizations in the pharmaceutical, biotech, life science, and other government-regulated industries
Owner
- Performance Cell Manufacturing, Inc., Poway, CA, US
- Performance Cell Manufacturing, Inc., Poway, CA, US
- Performance Cell Manufacturing, Inc., Poway, CA, US
Prosecution history
- 30 Apr 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 30 Apr 2024 — REGISTERED-PRINCIPAL REGISTER
- 29 Mar 2024 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 28 Mar 2024 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 04 Mar 2024 — STATEMENT OF USE PROCESSING COMPLETE
- 12 Feb 2024 — USE AMENDMENT FILED
- 04 Mar 2024 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 12 Feb 2024 — TEAS STATEMENT OF USE RECEIVED
- 29 Aug 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Jul 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Jul 2023 — PUBLISHED FOR OPPOSITION
- 14 Jun 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 01 Jun 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 May 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 24 May 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE